Tildren is an intravenous infusion prescribed for the control of clinical signs associated with navicular syndrome in horses four years and older. Navicular syndrome is a painful degenerative condition that affects the front feet of horses, more precisely the heel, of all breeds, which causes lameness. It can also happen to the back feet, but it is rare. The exact cause of Navicular syndrome is not known, but it might be due to the interference with blood supply or trauma to the bone. This condition affects not only the navicular bone but the surrounding tissues as well. The bone movement can cause inflammation and changes to the ligament and tendons of the heel, which causes pain. The skeletal bone tissue in adult horses undergoes a process of constant remodeling. This process allows the skeleton to adapt to your horse’s activity and workload. But when your horse suffers from navicular syndrome, excessive mechanical stress causes bone resorption to outpace bone formation. Tildren prevents the loss of bone mass and inhibits bone resorption, by blocking the activity of osteoclasts (bone cells), to increase bone density and to inhibit secretion of enzymes that degrade cartilage on joint surfaces. By reducing bone breakdown and further degeneration, Tildren reduces the pain that contributes to lameness.